[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Pharmacology](https://durgical.com/en/pharmacology/) › [PDE4 inhibitors](https://durgical.com/en/pharmacology/classes/pde4-inhibitors/) › Roflumilast

# Roflumilast

## PDE4 inhibitors?

PDE4 inhibitors

An oral PDE4 inhibitor that reduces flare-ups of severe COPD with chronic bronchitis; it is not a bronchodilator.

Updated Nov 1, 2026

## Quick facts

**Group**
[PDE4 inhibitors](https://durgical.com/en/pharmacology/classes/pde4-inhibitors/)

**Target**
Phosphodiesterase 4 (PDE4B, PDE4D)

**Used for**
Reducing the risk of exacerbations

**Key effects**
Diarrhoea and nausea · Headache and dizziness

**Monitor**
Body weight at regular visits · Mood

**ATC**
R03DX07

No doses: the clinician sets them by the current guideline.

On this page

- The basics Mechanism of action
- Indications
- Adverse effects
- Pharmacokinetics
- Memory aid

- Safety Contraindications
- Key interactions
- What is monitored
- Administration and safety
- Pregnancy and breastfeeding
- Nursing care

- Study Test yourself

- Connections Connections

## Mechanism of action

✂**Phosphodiesterase 4 (PDE4B, PDE4D)**Roflumilast

ⓘ The figure shows roflumilast bound to the catalytic domain of human phosphodiesterase 4B.

**Target in 3D:** Phosphodiesterase 4 (PDE4B, PDE4D). PDB structure 1XMU (RCSB PDB, public domain). [View the structure at RCSB PDB](https://www.rcsb.org/structure/1XMU) · Drag to rotate · pinch to zoom

Roflumilast and its active N-oxide metabolite selectively inhibit phosphodiesterase 4, the main enzyme that breaks down cyclic AMP in lung inflammatory and structural cells. Higher cyclic AMP reduces the release of inflammatory mediators and the influx of neutrophils into the airways. The result is fewer exacerbations in severe COPD with chronic bronchitis; lung function improves only slightly and there is no immediate bronchodilation.

- Roflumilast and its N-oxide block PDE4
- Cyclic AMP rises inside inflammatory cells
- Fewer cytokines are released and fewer neutrophils arrive
- COPD flare-ups become less frequent

## Indications

- Reducing the risk of exacerbations in severe COPD with chronic bronchitis and a history of exacerbations, added to bronchodilators [Chronic obstructive pulmonary disease (COPD) →](https://durgical.com/en/conditions/chronic-obstructive-pulmonary-disease/)

## Adverse effects

### Common

- Diarrhoea and nausea
- Weight loss and decreased appetite
- Headache and dizziness
- Insomnia and back pain

### Serious (rare, important)

- Psychiatric events: insomnia, anxiety, depression and suicidal thoughts or behaviour
- Clinically significant weight loss

## Contraindications

- Moderate to severe liver impairment (Child-Pugh B or C)
- Caution with a history of depression or suicidal thoughts
- Not for relief of acute bronchospasm

## Key interactions

**Strong CYP inducers: rifampicin, phenobarbital, carbamazepine, phenytoin**
Lower roflumilast exposure and make it less effective; not recommended

**CYP3A4 or dual CYP3A4/CYP1A2 inhibitors: erythromycin, ketoconazole, fluvoxamine, cimetidine**
Raise roflumilast exposure and side effects

## What is monitored

- Body weight at regular visits
- Mood, sleep and suicidal thoughts
- Exacerbation frequency
- Liver function before starting

## Administration and safety

- Oral tablet once a day, with or without food
- Some regimens start with a lower dose for a few weeks to improve tolerance
- Not a rescue medicine: the patient keeps a short-acting inhaler

## Pregnancy and breastfeeding

There are no adequate human data; it is not used in pregnancy unless the clinician judges the benefit worth the risk, and it is not used during breastfeeding.

## Nursing care

- Weigh the patient at each visit and report unexplained weight loss
- Ask about mood, sleep and suicidal thoughts; teach family to report changes
- Explain that diarrhoea and nausea often ease after the first weeks

## Pharmacokinetics

**Absorption**
Well absorbed by mouth

**Metabolism**
Liver: CYP3A4 and CYP1A2 form the active N-oxide, which provides most of the effect

**Elimination**
Urine, as metabolites

**Onset and duration**
Benefit on exacerbations builds over weeks to months

## Memory aid

ROFLumilast: Reduces Of Flare-ups, Loses weight, mood can drop.

## Test yourself

Think of the answer, then tap the question to see it.

## Is roflumilast a bronchodilator?

No; it is an anti-inflammatory PDE4 inhibitor that reduces exacerbations.

## Which COPD phenotype benefits from roflumilast?

Severe COPD with chronic bronchitis and frequent exacerbations.

## Which two things are monitored regularly during roflumilast treatment?

Body weight and mood (depression, suicidal thoughts).

## Why should rifampicin not be combined with roflumilast?

It induces CYP enzymes, lowers roflumilast exposure and makes it ineffective.

[Add to my cards (4)](https://durgical.app/estudiar/?add=/en/pharmacology/roflumilast/)

[More Pharmacology questions →](https://durgical.com/en/practice/?f=pharmacology)

## Connections

## Related drugs 3

- [Theophylline](https://durgical.com/en/pharmacology/theophylline/)
- [Tiotropium bromide](https://durgical.com/en/pharmacology/tiotropium-bromide/)
- [Salbutamol](https://durgical.com/en/pharmacology/salbutamol/)

## Related conditions 1

- [Chronic obstructive pulmonary disease (COPD)](https://durgical.com/en/conditions/chronic-obstructive-pulmonary-disease/)

[← Back to the class: PDE4 inhibitors](https://durgical.com/en/pharmacology/classes/pde4-inhibitors/)

Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given.

Sources: [DailyMed - ROFLUMILAST tablet](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaa81c1b-f63d-4e61-8bfa-9d42d92043c7) (DailyMed (U.S. National Library of Medicine), 2026); [Roflumilast: MedlinePlus Drug Information](https://medlineplus.gov/druginfo/meds/a611034.html) (MedlinePlus (U.S. National Library of Medicine), 2016); [ATCDDD - ATC/DDD Index](https://atcddd.fhi.no/atc_ddd_index/?code=R03DX07) (WHO Collaborating Centre for Drug Statistics Methodology, 2026).

## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake

Representative model, for educational purposes only.

---
Source: https://durgical.com/en/pharmacology/roflumilast/
License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/pharmacology/roflumilast/